Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
Tscherne A, Schwarz JH, Rohde C, Kupke A, Kalodimou G, Limpinsel L, Okba NMA, Bošnjak B, Sandrock I, Odak I, Halwe S, Sauerhering L, Brosinski K, Liangliang N, Duell E, Jany S, Freudenstein A, Schmidt J, Werner A, Gellhorn Serra M, Klüver M, Guggemos W, Seilmaier M, Wendtner CM, Förster R, Haagmans BL, Becker S, Sutter G, Volz A.
Tscherne A, et al. Among authors: seilmaier m.
Proc Natl Acad Sci U S A. 2021 Jul 13;118(28):e2026207118. doi: 10.1073/pnas.2026207118.
Proc Natl Acad Sci U S A. 2021.
PMID: 34162739
Free PMC article.